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ABSTRACT
Albuminuria may be a biomarker of generalized (i.e., microvascular and macrovascular) endothelial dysfunc-
tion. According to this concept, endothelial dysfunction of the renal microcirculation causes albuminuria by
increasingglomerular capillarywall permeability and intraglomerular pressure, the latter eventually leading to
glomerular capillary dropout (rarefaction) and further increases in intraglomerular pressure. However, direct
evidence for an association between capillary rarefaction and albuminuria is lacking. Therefore, we examined
the cross-sectional association between the recruitment of capillaries after arterial occlusion (capillary density
during postocclusive peak reactive hyperemia) and during venous occlusion (venous congestion), as assessed
with skin capillaroscopy, and albuminuria in 741 participants of the Maastricht Study, including 211 partici-
pants with type 2 diabetes. Overall, 57 participants had albuminuria, which was defined as a urinary albumin
excretion$30 mg/24 h. After adjustment for potential confounders, participants in the lowest tertile of skin
capillary recruitment during postocclusive peak reactive hyperemia had an odds ratio for albuminuria of 2.27
(95% confidence interval, 1.07 to 4.80) compared with those in the highest tertile. Similarly, a comparison
between the lowest and the highest tertiles of capillary recruitmentduring venous congestion yieldedanodds
ratio of 2.89 (95% confidence interval, 1.27 to 6.61) for participants in the lowest tertile. In conclusion, lower
capillary density of the skin microcirculation independently associated with albuminuria, providing direct
support for a role of capillary rarefaction in the pathogenesis of albuminuria.
J Am Soc Nephrol 27: 3748–3757, 2016. doi: 10.1681/ASN.2015111219
Albuminuria is strongly associated with cardiovas-
cular disease risk.1 A leading hypothesis to explain
this link is that albuminuria is a biomarker of gen-
eralized (i.e., microvascular and macrovascular)
endothelial dysfunction.2,3 According to this con-
cept, endothelial dysfunction of renal arterioles and
capillaries (i.e., the renal microcirculation) causes
albuminuria by increasing glomerular capillary
wall permeability and increasing intraglomerular
pressure,3 the latter eventually leading to glomerular
capillary dropout (rarefaction) and further increases
in intraglomerular pressure.4 Concomitantly, endo-
thelial dysfunction in coronary and carotid arteries
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(i.e., the macrocirculation) leads to atherothrombotic cardio-
vascular disease.2,3
Indeed, studies using flow-mediated dilation of the bra-
chial,5–9 femoral,10 and left anterior descending coronary
artery11 have provided strong direct evidence for the presence
of endothelial dysfunction in the macrocirculation of individ-
uals with albuminuria.
In contrast, evidence for endothelial dysfunction in the
microcirculation of individuals with albuminuria is primarily
indirect, because it derives from studies using plasma bio-
markers,12–17 the transcapillary escape rate of albumin,18–21
strain-gauge plethysmography after forearm ischemia,22 and
laser Doppler flowmetry after either iontophoresis of acetyl-
choline and sodium nitroprusside23 or arterial occlusion.24 In
addition, evidence for an association between capillary rare-
faction and albuminuria is confined to a relatively small study,
which showed the frequent co-occurrence of both in individ-
uals with hypertension.25
In view of these considerations, we examined in a pop-
ulation–based cohort study the hypothesis that capillary rare-
faction is associatedwith albuminuria. To do this, we used skin
capillaroscopy, because capillary rarefaction in the kidney can-
not be studied noninvasively in humans. Skin capillaroscopy
is a noninvasive technique that allows direct visualization of
capillary density in skin by measuring the recruitment of
capillaries in response to arterial and venous occlusion,
which are thought to be measures of functional and structural
capillary density.26
RESULTS
Characteristics of the Study Population
For this study on the basis of the first dataset of the Maastricht
Study (n=866), four participants with type 1 diabetes were
excluded. In the remaining 862 participants, qualitatively sat-
isfactory data on skin capillaroscopy were available in 818
participants. In another 12 participants, the 24-hour urine
collections either were collected erroneously (,20 or .28
hours) or were not handed in at all. Of the remaining 806
participants, we additionally excluded participants with miss-
ing data on waist circumference (n=3), smoking behavior
(n=14), alcohol consumption (n=17), total cholesterol-to-
HDL cholesterol ratio (n=8), triglycerides (n=7), eGFR
(n=15), office BP (n=2), and/or prior cardiovascular disease
status (n=32). Thesemissing datawere notmutually exclusive.
The study population, therefore, consisted of 741 participants.
Table 1 shows the clinical characteristics of the study pop-
ulation stratified according to tertiles of the percentage
recruitment during postocclusive peak reactive hyperemia.
Tertile 1 indicates the tertile with the highest level of capillary
recruitment.
In general, participants with the lowest recruitment were
more often men, were less educated, suffered more often from
hypertension and type 2 diabetes, and were more often treated
with lipid-modifying or antihypertensive medication. Clinical
characteristics according to tertiles of the percentage recruit-
ment during venous congestion are shown in Supplemental
Table 1.
Recruitment of Skin Capillaries and the Presence of
Albuminuria
Overall, participants with the lowest recruitment more often
had albuminuria (Figure 1).
After adjustment for potential confounders and compared
with participants with the highest percentage recruitment
during postocclusive peak reactive hyperemia (reference
category), the odds ratio (OR) and 95% confidence interval
(95% CI) for albuminuria for participants in the lowest tertile
were OR, 2.27 and 95% CI, 1.07 to 4.80 (Table 2, model 3a).
After adjustment for potential confounders and compared
with participants with the highest percentage recruitment
during venous congestion (reference category), the OR
(95% CI) for albuminuria for participants in the lowest tertile
was 2.89 (95% CI, 1.27 to 6.61) (Table 2, model 3a).
When we replaced office systolic BP with 24-hour average
ambulatory systolic BP (n=665), the OR (95% CI) for albu-
minuria became 2.19 (95% CI, 0.96 to 5.00) for those with the
lowest percentage recruitment during postocclusive peak re-
active hyperemia (Table 2, model 3b) and 2.68 (95% CI, 1.10
to 6.52) for those with the lowest percentage recruitment dur-
ing venous congestion (Table 2, model 3b).
Whenwereplaced thepercentage change in capillarydensity
with the absolute numbers of capillaries during postocclusive
peak reactive hyperemia as well as during venous congestion,
the results were similar (Table 3).
When the variables of models 3a and 3b were added
separately to a model adjusted for age and sex, adjustment for
type 2 diabetes led to the largest reduction of the OR when the
percentage recruitment was the determinant. When the
absolute number of capillaries was the determinant, adding
additional variables after initial adjustment for age and sex did
not materially alter our results (data not shown).
Analyses with interaction terms suggested that the associ-
ations between the percentage recruitment during postocclu-
sive peak reactive hyperemia as well as venous congestion and
albuminuria were only present in individuals without type 2
diabetes (P value of the interaction term [Pinteraction] ,0.10)
(Supplemental Table 2), whereas no such interaction was ob-
served for the absolute number of capillaries under both con-
ditions (Pinteraction.0.10) (Supplemental Table 3).
Additional Analyses
First, recruitment of capillaries may be expressed as either the
absolute or percentage change in capillary density (Concise
Methods). When we replaced the percentage change with
absolute change in capillary density, results were notmaterially
altered for either postocclusive peak reactive hyperemia or
venous congestion (data not shown). Second, mutual adjust-
ment for the percentage recruitment during venous congestion
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Table 1. Clinical characteristics of the study population according to tertiles of the percentage recruitment during
postocclusive peak reactive hyperemia
Characteristic
Tertiles of the Percentage Recruitment during
Postocclusive Peak Reactive Hyperemia
Tertile 1 (High), n=247 Tertile 2 (Middle), n=247 Tertile 3 (Low), n=247
Recruitment during postocclusive peak reactive hyperemia, % 73.7 [55.0–186.7] 38.9 [27.0–54.9] 16.3 [0.0–26.9]
Demographics
Age, yr 59.268.5 60.068.6 60.068.5
Men 119 (48.2) 143 (57.9) 150 (60.7)
Educational level
Low 33 (13.4) 37 (15.0) 50 (20.2)
Middle 95 (38.5) 101 (40.9) 110 (44.5)
High 119 (48.2) 109 (44.1) 87 (35.2)
Prior cardiovascular disease 50 (20.2) 36 (14.6) 48 (19.4)
Lifestyle variables
Smoking behavior
Never a smoker 80 (32.4) 78 (31.6) 72 (29.1)
Former smoker 128 (51.8) 132 (53.4) 136 (55.1)
Current smoker 39 (15.8) 37 (15.0) 39 (15.8)
Alcohol consumption
None 34 (13.8) 42 (17.0) 47 (19.0)
Low: women #7 glasses per wk; men #14 glasses per wk 126 (51.0) 135 (54.7) 131 (53.0)
High: women .7 glasses per wk; men .14 glasses per wk 87 (35.2) 70 (28.3) 69 (27.9)
Metabolic variables
Body mass index categories
Normal weight, ,25 kg/m2 81 (32.8) 86 (34.8) 67 (27.1)
Overweight, 25–30 kg/m2 117 (47.4) 106 (42.9) 122 (49.4)
Obesity, $30 kg/m2 49 (19.8) 55 (22.3) 58 (23.5)
Waist circumference, cm
Men 100.9611.7 101.3611.6 103.2611.5
Women 89.5612.1 91.5613.7 92.4614.3
Waist-to-hip ratio
Men 1.0060.07 1.0060.06 1.0160.07
Women 0.8760.07 0.8860.07 0.8960.08
Office systolic BP, mmHg 136.1618.2 135.9618.7 140.0619.9
Office diastolic BP, mmHg 76.5610.3 76.0610.8 77.8610.5
24-h Average ambulatory systolic BP, mmHga 118.3611.9 119.3611.9 120.9612.6
24-h Average ambulatory diastolic BP, mmHga 73.667.4 74.367.4 74.667.1
Hypertension 136 (55.1) 136 (55.1) 158 (64.0)
Glucose metabolism status
Normal glucose metabolism 151 (61.1) 139 (56.3) 114 (46.2)
Impaired fasting glucose 10 (4.0) 11 (4.5) 19 (7.7)
Impaired glucose tolerance 43 (17.4) 27 (10.9) 16 (6.5)
Type 2 diabetes 43 (17.4) 70 (28.3) 98 (39.7)
Fasting glucose, mmol/L
Without type 2 diabetes 5.460.6 5.460.6 5.560.6
With type 2 diabetes 7.961.7 7.661.4 7.761.9
HbA1C, %b
Without type 2 diabetes 5.760.4 5.660.4 5.660.3
With type 2 diabetes 6.960.8 6.760.7 6.960.9
Total cholesterol, mmol/L 5.461.2 5.261.2 5.061.1
HDL cholesterol, mmol/L
Men 1.260.5 1.160.3 1.160.3
Women 1.560.4 1.560.4 1.560.5
LDL cholesterol, mmol/L 3.461.1 3.361.0 3.161.0
Triglycerides, mmol/L 1.20 [0.79–1.75] 1.26 [0.89–1.78] 1.25 [0.89–1.79]
Total cholesterol-to-HDL cholesterol ratio 4.261.2 4.361.3 4.161.2
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or the percentage recruitment during postocclusive peak
reactive hyperemia suggested multicollinearity (i.e., a strong
increase in the standard error of the regression coefficient of
the central determinant; data not shown). Third, results were
not materially altered when we excluded participants with an
albumin excretion .300 mg/24 h; when we replaced office
systolic BP with office diastolic BP, office pulse pressure, office
mean arterial pressure, presence of hypertension, 24-hour av-
erage ambulatory diastolic BP, 24-hour average ambulatory
pulse pressure, or 24-hour average ambulatory mean arterial
pressure; when we replaced the use of antihypertensive med-
ication with the use of a renin-angiotensin system inhibitor,
the use of a diuretic, or their combined use;
whenwe replaced waist circumference with
waist-to-hip ratio or body mass index;
when we replaced the total cholesterol-to-
HDL cholesterol ratio with LDL and HDL;
or when we additionally adjusted for he-
moglobin A1c (HbA1c) or an inflamma-
tion Z score (n=738). Fourth, analyses in
the subpopulation with two urine collec-
tions (n=666) and the subset of 24-hour
urine collections with measured 24-hour
urine creatinine excretion within 30% of
expected values (n=642) did not indicate
nondifferential misclassification caused by
biologic variability and inaccurate collec-
tion, respectively (data not shown). Fifth,
analyses on the basis of quintiles and dec-
iles of the respective capillaroscopy mea-
sures were also consistent with a threshold
level (Supplemental Tables 4–6). However,
these analyses were hampered by a loss of
power. Sixth, we defined albuminuria as
an albumin excretion $15 mg/24 h, in
agreement with the fact that an associa-
tion with (cardiovascular disease) mortal-
ity already exists at levels of urinary
albumin excretion ,30 mg/24 h1 and to
explore whether misclassification of
albuminuria status occurred with the
clinical cutoff value. With this definition,
the associations for the entire study
Figure 1. Capillary recruitment is associated with albuminuria. Bar charts showing the
association between recruitment during postocclusive peak reactive hyperemia (left
panel) as well as during venous congestion (right panel) and the presence of albu-
minuria $30 mg/24 h. Tertiles of the percentage recruitment during postocclusive
peak reactive hyperemia ranged from 55.0 to 186.7 (tertile 1 [T1]), from 27.0 to 54.9
(tertile 2 [T2]), and from 0.0 to 26.9 (tertile 3 [T3]). Tertiles of the percentage re-
cruitment during venous congestion ranged from 55.8 to 253.3 (T1), from 27.6 to 55.7
(T2), and from 22.9 to 27.5 (T3). Percentages of participants with albuminuria $30
mg/24 h per tertile were adjusted for age, sex, and type 2 diabetes (model 2) by
marginal standardization. P values were derived from the same models.
Table 1. Continued
Characteristic
Tertiles of the Percentage Recruitment during
Postocclusive Peak Reactive Hyperemia
Tertile 1 (High), n=247 Tertile 2 (Middle), n=247 Tertile 3 (Low), n=247
Kidney function
eGFR, ml/min per 1.73 m2 88.7614.7 87.6614.5 87.8616.0
Albumin excretion rate, mg/24 h 8.2 [5.4–11.6] 7.8 [5.5–11.5] 7.8 [5.5–15.7]
Albumin excretion $15 mg/24 h 34 (13.8) 37 (15.0) 64 (25.9)
Albumin excretion $30 mg/24 h 12 (4.9) 13 (5.3) 32 (13.0)
Medication
Antihypertensive medication 94 (38.1) 89 (36.0) 113 (45.7)
Renin-angiotensin system inhibitor 75 (30.4) 65 (26.3) 84 (34.0)
Lipid-modifying medication 87 (35.2) 78 (31.6) 106 (42.9)
Data are presented as n (%), mean6SD,median [interquartile range], or (only for the percentage recruitment during postocclusive peak reactive hyperemia) median
[range].
aTwenty-four–hour average ambulatory BP measurements were missing in n=76 participants (n=27 for tertile 1, n=23 for tertile 2, and n=26 for tertile 3).
bTo convert to HbA1c values into millimoles per mole: (10.933 HbA1c [%])223.5.
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population became somewhat weaker (Supplemental Table
7), and there was no statistical interaction with type 2 di-
abetes (Pinteraction.0.10). Seventh, multivariable linear re-
gression analyses showed no associations between tertiles of
the respective capillaroscopy measures and (inverse square
root–transformed) continuous urinary albumin excretion
(data not shown).
DISCUSSION
The main finding of this population-based study is that lower
capillary density was associated with the presence of albumin-
uria, regardless of whether type 2 diabetes was present. This
association was independent of cardiovascular disease risk
factors, including 24-hour average ambulatory BP and bio-
markers of low-grade inflammation. To the best of our knowl-
edge, this is the first population-based study that provides
direct support for a role of capillary rarefaction in the path-
ogenesis of albuminuria.
An association between capillary rarefaction and albumin-
uria is in agreement with the Brenner hypothesis4 (i.e., an
increase in intraglomerular pressure will lead to glomerular
capillary dropout [rarefaction] and further increases in intra-
glomerular pressure on the one hand and greater permeation
of albumin through the glomerular capillary wall on the other
hand). Indeed, in individuals with type 2 diabetes, estimated
intraglomerular pressure was higher in the presence of albu-
minuria.27 Additionally, in individuals who underwent a large
reduction in renal mass, remaining kidney mass was inversely
associated with urinary albumin excretion.28 Furthermore,
in a smaller study, capillary rarefaction in the skin microcir-
culation and albuminuria frequently co-occurred in individ-
uals with hypertension.25 This study extends this knowledge,
because it is the first to examine a direct measure of capillary
rarefaction in a large population–based sample with adjust-
ment for potential confounders.
A key assumption underlying this study is that skin capillary
rarefaction reflects capillary rarefaction of the kidney. Al-
though the skin microcirculation has not been compared
directly with that of the kidney, several observations support
the view that it is representative for the systemic microcircu-
lation, including the kidney’s. First, age-related changes in the
skin microcirculation parallel those in the systemic vascula-
ture.29 Second, the microcirculation of the skin and kidney
share associations with salt-sensitive hypertension30 and low
birth weight.31–34
Both capillary density during venous occlusion and capil-
lary density after arterial occlusion were used as reproduc-
ible26,35 estimates of maximal skin capillary density.36 In this
study, we could not determine to what extent differences in
capillary density were caused by structural (i.e., anatomic) or
functional (i.e., nonperfusion) rarefaction. However, the oc-
currence ofmulticollinearity after mutual adjustment suggests
that both measures assessed the same or at least overlapping
construct(s) in this study.
Importantly, misclassification of albuminuria status be-
cause of the use of renin-angiotensin system inhibitors may
explain why capillary rarefaction in individuals with type 2
diabetes was associated with albuminuria when defined as an
albumin excretion $15 mg/24 h but not when defined as an
albumin excretion $30 mg/24 h. Renin-angiotensin system
inhibitors reduce urinary albumin excretion by lowering in-
traglomerular pressure,37,38 an effect that is enhanced by
Table 2. Association between the percentage recruitment
during postocclusive peak reactive hyperemia as well as
venous congestion and the presence of albuminuria (albumin
excretion $30 mg/24 h)
Independent Variable OR (95% CI) P Value
Recruitment during postocclusive
peak reactive hyperemia, %
Model 1
Tertile 1 (high) Reference
Tertile 2 (middle) 1.09 (0.49 to 2.43) 0.84
Tertile 3 (low) 2.92 (1.46 to 5.80) 0.002
Model 2
Tertile 1 (high) Reference
Tertile 2 (middle) 0.82 (0.36 to 1.88) 0.57
Tertile 3 (low) 2.04 (0.99 to 4.19) 0.05
Model 3a
Tertile 1 (high) Reference
Tertile 2 (middle) 0.95 (0.41 to 2.30) 0.95
Tertile 3 (low) 2.27 (1.07 to 4.80) 0.03
Model 3b
Tertile 1 (high) Reference
Tertile 2 (middle) 1.25 (0.50 to 3.13) 0.63




Tertile 1 (high) Reference
Tertile 2 (middle) 1.83 (0.79 to 4.23) 0.16
Tertile 3 (low) 3.94 (1.84 to 8.43) ,0.001
Model 2
Tertile 1 (high) Reference
Tertile 2 (middle) 1.56 (0.66 to 3.67) 0.31
Tertile 3 (low) 2.75 (1.25 to 6.06) 0.01
Model 3a
Tertile 1 (high) Reference
Tertile 2 (middle) 1.75 (0.72 to 4.26) 0.74
Tertile 3 (low) 2.89 (1.27 to 6.61) 0.01
Model 3b
Tertile 1 (high) Reference
Tertile 2 (middle) 1.79 (0.69 to 4.65) 0.23
Tertile 3 (low) 2.68 (1.10 to 6.52) 0.03
ORs represent the odds of having albuminuria (defined as an albumin ex-
cretion$30 mg/24 h) in the respective tertile of the percentage recruitment
during postocclusive peak reactive hyperemia or venous congestion com-
pared with the odds of having albuminuria in the reference tertile. Model 1 is
the unadjusted model. Model 2 is adjusted for age, sex, and type 2 diabetes.
Model 3a is model 2 adjusted for waist circumference, total cholesterol-to-
HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office sys-
tolic BP, use of antihypertensive medication, eGFR, prevalent cardiovascular
disease, smoking behavior, alcohol consumption, and educational level.
Model 3b is model 3a adjusted for 24-hour average ambulatory systolic BP
instead of office systolic BP (n=665).
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diuretics,39 and an albumin excretion$30 mg/24 h is used as
an indication for their use, particularly in individuals with
type 2 diabetes.40 Hence, individuals previously having had
an albumin excretion $30 mg/24 h could be classified erro-
neously as having no albuminuria with this definition, thus
obscuring an association with capillary rarefaction. Indeed,
the frequent use of renin-angiotensin system inhibitors in in-
dividuals with type 2 diabetes and a urinary albumin excretion
of 15–30 mg/24 h (64.9% versus 19.5% in individuals with a
similar urinary albumin excretion but without type 2 diabetes)
supports this explanation. Alternatively, the statistically sig-
nificant interaction between type 2 diabetes and the percent-
age recruitment during postocclusive peak reactive hyperemia
as well as venous congestion may be attributable to the play of
chance given the low number of cases.
A lack of power because of the small variation in urinary
albumin excretionwith only a few individuals with an albumin
excretion $30 mg/24 h may explain why the results of this
study suggest a threshold level for capillary density and why
capillary rarefaction was not associated with continuous uri-
nary albumin excretion. In addition, we measured urinary
albumin excretion instead of the permeation of albumin through
the glomerular capillary wall, and small increases in permeation
may be compensated for by tubular reabsorption.41
A strength of this study is that participants of theMaastricht
Study were well characterized, allowing adjustment for an
extensive series of potential confounders, including 24-hour
average ambulatory BP and low-grade inflammation. In this
regard, the use of office BPonly could have underestimated any
effect of BP on albuminuria and thereby, overestimated the
association between capillary rarefaction and albuminuria.
However, some of the variables in our models may also be
intermediates in the association between capillary rarefaction
and albuminuria, possibly leading to overadjustment bias (i.e.,
the associations reported are conservative).42 For instance,
capillary rarefaction may be involved in the pathogenesis of
type 2 diabetes, which may subsequently lead to albuminuria
via a hyperglycemia-induced increase in glomerular capillary
wall permeability.3 Similarly, higher BP may be both a cause
and a consequence of capillary rarefaction.43
From a clinical perspective, both capillary rarefaction itself
and the resulting increase in intraglomerular pressuremay be a
target in the management of albuminuria. Indeed, renin-
angiotensin system inhibitors, which reduce intraglomerular
pressure,37,38 form themainstay of the currentmanagement of
albuminuria.40 However, current management is not specifi-
cally aimed at regenerating glomeruli. Nonetheless, in a recent
study, treatment with a renin-angiotensin system inhibitor led
to an increase in kidney vasculature in a rat model of progres-
sive glomerular injury,44 suggesting that capillary rarefaction
itself could be a future therapeutic target.
This study had some limitations. First, no direct measure of
capillary rarefaction of the kidney was used. However, at
present, capillary rarefaction of the kidney, in contrast to
capillary rarefactionof skin, cannotbe studiednoninvasively in
humans. Second, because of the logistics of this large–scale
population–based study, participants were not asked to
come in fasting. However, to minimize the effects of dietary
intake on themicrocirculation,45–47 participants were asked to
have a standardized low–fat breakfast (or lunch) and refrain
from caffeine-containing beverages and smoking. In addition,
results were not materially altered after adjustment for non-
adherence to the dietary and smoking restrictions. Third, the
Table 3. Association between the absolute number of
capillaries during postocclusive peak reactive hyperemia as
well as venous congestion and the presence of albuminuria
(albumin excretion $30 mg/24 h)




Tertile 1 (high) Reference
Tertile 2 (middle) 2.51 (1.13 to 5.57) 0.02
Tertile 3 (low) 3.01 (1.38 to 6.55) ,0.01
Model 2
Tertile 1 (high) Reference
Tertile 2 (middle) 2.27 (1.00 to 5.15) 0.05
Tertile 3 (low) 2.38 (1.07 to 5.31) 0.03
Model 3a
Tertile 1 (high) Reference
Tertile 2 (middle) 2.63 (1.10 to 6.30) 0.03
Tertile 3 (low) 2.61 (1.11 to 6.12) 0.03
Model 3b
Tertile 1 (high) Reference
Tertile 2 (middle) 2.09 (0.82 to 5.30) 0.12
Tertile 3 (low) 2.51 (1.04 to 6.06) 0.04
Venous congestion, n/mm2
Model 1
Tertile 1 (high) Reference
Tertile 2 (middle) 1.15 (0.55 to 2.41) 0.72
Tertile 3 (low) 2.11 (1.08 to 4.13) 0.03
Model 2
Tertile 1 (high) Reference
Tertile 2 (middle) 0.95 (0.44 to 2.04) 0.90
Tertile 3 (low) 1.72 (0.86 to 3.47) 0.13
Model 3a
Tertile 1 (high) Reference
Tertile 2 (middle) 1.12 (0.50 to 2.50) 0.79
Tertile 3 (low) 1.76 (0.84 to 3.69) 0.13
Model 3b
Tertile 1 (high) Reference
Tertile 2 (middle) 1.32 (0.54 to 3.25) 0.54
Tertile 3 (low) 2.32 (1.01 to 5.32) 0.05
ORs represent the odds of having albuminuria (defined as an albumin ex-
cretion $30 mg/24 h) in the respective tertile of the absolute number of
capillaries during postocclusive peak reactive hyperemia or venous con-
gestion compared with the odds of having albuminuria in the reference
tertile. Model 1 is the unadjusted model. Model 2 is adjusted for age, sex,
and type 2 diabetes. Model 3a is model 2 adjusted for waist circumference,
total cholesterol-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying
drugs, office systolic BP, use of antihypertensive medication, eGFR, prevalent
cardiovascular disease, smoking behavior, alcohol consumption, and educa-
tional level. Model 3b is model 3a adjusted for 24-hour average
ambulatory systolic BP instead of office systolic BP (n=665).
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cross-sectional design does not allow us to make strong causal
inferences. In addition, a longitudinal design with frequent
assessment of urinary albumin excretion and medication use
would have avoided misclassification of albuminuria status.
Fourth, the study population primarily consisted of white in-
dividuals of European descent (99.2%), limiting generalizabil-
ity to other populations.
In conclusion, lower capillary density of the skin microcir-
culation was independently associated with the presence of
albuminuria, regardless of the presence of type 2 diabetes.
Thereby, this is the first population-based study that provides
direct support for a role of capillary rarefaction in the patho-
genesis of albuminuria.
CONCISE METHODS
The Maastricht Study Population and Design
In this study,weuseddata fromtheMaastricht Study, anobservational
prospective population–based cohort study. The rationale and meth-
odology have been described previously.48 In brief, the study focuses
on the etiology, pathophysiology, complications, and comorbidities
of type 2 diabetes mellitus and is characterized by an extensive phe-
notyping approach. Eligible for participation were all individuals
with ages between 40 and 75 years living in the southern part of
The Netherlands. Participants were recruited through mass media
campaigns and from the municipal registries and the regional Dia-
betes Patient Registry viamailings. Recruitment was stratified accord-
ing to known type 2 diabetes status for reasons of efficiency. This
report includes cross-sectional data from the first 866 participants
who completed the baseline survey between November of 2010 and
March of 2012. The examinations of each participant were performed
within a time window of 3 months. The study has been approved
by the institutionalmedical ethical committee (NL31329.068.10) and
the Minister of Health, Welfare and Sports of The Netherlands on the
basis of the Health Council’s opinion (Permit 131088–105234-PG)
and was conducted in accordance with the Declaration of Helsinki.
All participants gave written informed consent.
Skin Capillaroscopy
All participants were asked to refrain from smoking and drinking
coffee or tea$3 hours before the measurements. A light meal (break-
fast and/or lunch) low in fat content was allowed before the start of
the measurements. Skin capillaroscopy measurements were per-
formed in a quiet, temperature–controlled room (T=24°C) with par-
ticipants in the supine position as previously described.49
Briefly, capillaries were visualized in the dorsal skin of the distal
phalanges of the third and fourth finger of the right hand by use of a
digital video microscope (Capiscope; KK Technology, Honiton,
United Kingdom) with a systemmagnification of3100.49 Capillaries
were visualized 4.5 mm proximal to the terminal row of capillaries in
the middle of the nailfold. The investigator selected a region of in-
terest of 1-mm2 skin area. Capillary density (mean of two fields) was
measured under three conditions. First, baseline capillary density was
measured. Baseline capillary density was defined as the number of
continuously erythrocyte–perfused capillaries per 1 mm2 skin and
was counted for 15 seconds. Second, capillary recruitment during
postocclusive peak reactive hyperemia was assessed after 4 minutes
of arterial occlusion. Arterial occlusionwas applied using aminiature
cuff at the base of the investigated finger inflated to suprasystolic pres-
sure (260 mmHg) for 4 minutes. Directly after release of the cuff, all
(continuously and intermittently) perfused capillaries were counted for
15 seconds. Third, venous congestionwas applied, with the cuff inflated
to 60 mmHg for 2 minutes, and all (continuously and intermittently)
perfused capillaries were counted for 15 seconds. The number of per-
fused capillaries was counted in the recorded digital raw data with the
use of a semiautomatic procedure (CapiAna)49 by two investigatorswho
were blinded toparticipants’ clinical status. The intra- and interobserver
coefficients of variation for the counting procedure were 2.5% and
5.6%, respectively, as described previously.49
For the primary analyses, we used recruitment during postocclu-
sive peak reactive hyperemia as well as during venous congestion
(expressed as thepercentage change in capillarydensity frombaseline)
and the absolute number of capillaries during postocclusive peak
reactive hyperemia as well as during venous congestion (expressed as
capillaries per 1 mm2).
Kidney Function
GFR was estimated using the Chronic Kidney Disease Epidemiology
Collaboration equation on the basis of both serum creatinine and
serum cystatin C (Supplemental Material).50 To assess urinary albu-
min excretion, participants were requested to collect two 24-hour
urine collections (Supplemental Material).
Albuminuria was defined as an albumin excretion$30mg/24 h,51
which is used in clinical practice to guide cardiovascular disease pre-
vention, particularly in individuals with type 2 diabetes.40 In an ad-
ditional analysis, albuminuria was defined as an albumin excretion
$15 mg/24 h (the upper level of daily albumin excretion in healthy
individuals52) in agreement with the fact that an association with
(cardiovascular disease) mortality already exists at levels of urinary
albumin excretion ,30 mg/24 h1 and to explore whether misclassi-
fication of albuminuria status occurred with the clinical cutoff.
These definitions were preferably on the basis of the average of two
(available in 89.9% of the participants) 24-hour urine collections.
Potential Confounders
We assessed glucose metabolism status, body mass index, waist
circumference, hip circumference, office BP, 24-hour average ambu-
latory BP, fasting glucose, HbA1c, total cholesterol, HDL cholesterol,
LDL cholesterol, triglycerides, medication use, smoking behavior,
alcohol consumption, educational level, and prevalent cardiovascular
disease as described previously.48,53 Definitions of these potential
confounders are provided in Supplemental Material. In addition,
we assessed the following plasma biomarkers of inflammation:
high–sensitivity C–reactive protein, serum amyloid A, IL-6, IL-8,
TNF-a, and soluble intercellular adhesion molecule 1.54
Statistical Analyses
All analyses were performed with IBM SPSS Statistics, Version 22.0
(IBM SPSS, Chicago, IL) unless stated otherwise.
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Participants were divided into tertiles of the percentage recruit-
ment during postocclusive peak reactive hyperemia as well as into
tertiles of the percentage recruitment during venous congestion,
because the association with albuminuria seemed to be nonlinear.
Participants with normal glucose tolerance, impaired fasting glucose,
and impaired glucose tolerance were combined into one category
(participants without type 2 diabetes) because of the small number of
participants with impaired fasting glucose and impaired glucose
tolerance.
Associations between tertiles of the percentage recruitment during
postocclusive peak reactive hyperemia as well as during venous
congestion and the presence of albuminuria were evaluated using
multivariable logistic regression analyses. Similarly, associations
between tertiles of the absolute number of capillaries during post-
occlusive peak reactive hyperemia as well as during venous congestion
and the presence of albuminuria were evaluated. The tertile with the
highest recruitment or the highest absolute number of capillaries
(tertile 1) was used as reference category. Next, we adjusted for
potential confounders as follows: model 1, unadjusted model; model
2, adjusted for age, sex, and type 2diabetes;model 3a,model 2 adjusted
for waist circumference, total cholesterol-to-HDL cholesterol ratio,
triglycerides, use of lipid-modifyingmedication, office systolic BP, use
of antihypertensive medication, eGFR, prevalent cardiovascular
disease, smoking behavior, alcohol consumption, and educational
level; andmodel 3b,model 3awith replacement of office systolic BP by
24-hour average ambulatory systolic BP.
We used interaction terms to examine whether the associations
were modified by the presence or absence of type 2 diabetes. A
Pinteraction,0.10 in model 3a was considered to indicate a statisti-
cally significant interaction.
Adjusted percentages of participants with albuminuria per tertile
of recruitment were derived from the logistic regression models
(model 2)withadjustment forage, sex, and type2diabetesbymarginal
standardization55 (calculated with Stata Statistical Software, release
11.2SE; StataCorp., College Station, TX).
Several additional analyses were performed, each starting from the
models described above. First,weused the absolute change in capillary
density from baseline (expressed as capillaries per 1 mm2) during
postocclusive peak reactive hyperemia and during venous congestion
to categorize participants. Second, we excluded participants with an
albumin excretion .300 mg/24 h (n=8). Third, we replaced office
systolic BP with office diastolic BP, office pulse pressure, office mean
arterial pressure, presence of hypertension, 24-hour average ambu-
latory diastolic BP, 24-hour average ambulatory pulse pressure, or 24-
hour average ambulatory mean arterial pressure in model 3a, and we
replaced the use of antihypertensive medication with the use of a
renin-angiotensin system inhibitor, the use of a diuretic, or their
combined use. Fourth, we replaced waist circumference with waist-
to-hip ratio or body mass index, replaced the total cholesterol-to-
HDL cholesterol ratio with LDL and HDL, and additionally, adjusted
for HbA1c and a Z score of the inflammation biomarkers54 in model
3a. Fifth, we repeated the analyses in participants with two urine
collections and after exclusion of 24-hour urine collections with a
measured 24-hour urine creatinine excretion not within 30% of ex-
pected values56 to explore whether biologic variation and inaccurate
collection, respectively, led to nondifferential misclassification with
bias toward zero. Sixth, we repeated the analyses with quintiles and
deciles of the respective capillaroscopy measures as independent var-
iables. Seventh, we repeated the analyses with albuminuria defined as
an albumin excretion$15mg/24 h. Eighth, we performedmultivari-
able linear regression analyses to examine whether the capillaroscopy
measures were associated with urinary albumin excretion on a con-
tinuous scale. Urinary albumin excretion had to be transformed
by taking the inverse square root of urinary albumin excretion to
fulfill the normality assumption, because it was highly positively
skewed and could not be transformed adequately using common57
transformations.
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GFR was estimated using the CKD-EPI equation based on both serum creatinine and 
serum cystatin C.1 Serum creatinine was measured with a Jaffé method traceable to 
isotope dilution mass spectrometry (Beckman Synchron LX20, Beckman Coulter Inc., 
Brea, USA). Serum cystatin C was measured with a particle enhanced 
immunoturbidimetric assay standardized against ERM-DA471/IFCC reference 
material (Roche Cobas 8000, F. Hoffman-La Roche Ltd, Basel, Switzerland). 
To assess urinary albumin excretion, participants were requested to collect two 24h 
urine collections. Urinary albumin concentration was measured with a standard 
immunoturbidimetric assay by an automatic analyzer (Beckman Synchron LX20, 
Beckman Coulter Inc., Brea, USA) and multiplied by collection volume to obtain the 
24h urinary albumin excretion. A urinary albumin concentration below the detection 
limit of the assay (2 mg/l) was set at 1.5 mg/l before multiplying by collection volume. 
Only urine collections with a collection time between 20h and 28h were considered 
valid. If needed, urinary albumin excretion was extrapolated to a 24h excretion.  
Albuminuria was defined as an albumin excretion ≥ 30 mg/24h,2 which is used in 
clinical practice to guide cardiovascular disease prevention, particularly in individuals 
with type 2 diabetes.3  In an additional analysis, albuminuria was defined as an 
albumin excretion ≥ 15 mg/24h (the upper level of daily albumin excretion in healthy 
individuals4), in agreement with the fact that an association with (cardiovascular) 
mortality already exists below the clinical cut off value of 30 mg/24h.5 These 
definitions were preferably based on the average of two (available in 89.9% of the 





We assessed glucose metabolism status, body mass index, waist circumference, hip 
circumference, office blood pressure, 24h average ambulatory blood pressure, 
fasting glucose, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, medication use, smoking behavior, alcohol consumption, educational 
level and prevalent cardiovascular disease as described previously.6,7 Glucose 
metabolism status was classified according to the World Health Organization 2006 
criteria8 into normal glucose metabolism, impaired fasting glucose, impaired glucose 
tolerance, and diabetes mellitus. Participants with diabetes mellitus and participants 
using glucose-lowering medication were considered as having type 2 diabetes if they 
had no (self-reported) type 1 or other specific type of diabetes. Prevalent 
cardiovascular disease was defined as a self-reported history of myocardial 
infarction, and(or) cerebrovascular infarction or hemorrhage, and(or) percutaneous 
artery angioplasty of, or vascular surgery on, the coronary, abdominal, peripheral or 
carotid arteries. Alcohol consumption was classified into three categories: non-
consumption, low-consumption (<7 glasses per week for women and <14 glasses per 
week for men) and high-consumption (>7 glasses per week for women and >14 
glasses per week for men). Waist-to-hip ratio was calculated by dividing waist 
circumference by hip circumference. Total-to-HDL cholesterol ratio was calculated by 
dividing total cholesterol by HDL cholesterol. Hypertension was defined as an office 
systolic blood pressure ≥ 140 mmHg, an office diastolic blood pressure ≥ 90 mmHg 
and(or) the use of antihypertensive medication. Office pulse pressure was defined as 
office systolic blood pressure minus office diastolic blood pressure and office mean 
arterial pressure as office diastolic blood pressure plus 0.412 times office pulse 
pressure.9 Similar equations were used to calculate 24h average ambulatory pulse 
4 
 
pressure and 24h average ambulatory mean arterial pressure, respectively. 
Educational level was assessed during the cognitive assessment and was classified 
into three groups: low (none, primary, or lower vocational education only), 
intermediate (intermediate general secondary, intermediate vocational or higher 
general secondary education) and high (higher vocational education or university 
level of education).7,10 
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Supplemental Table 1. Clinical characteristics of the study population according to tertiles of the 
percentage recruitment during venous congestion 
 
Tertiles of the percentage recruitment during venous 
congestion 
 T1 (high) T2 (middle) T3 (low) 
 n = 247 n = 247 n = 247 
Recruitment during venous congestion (%) 75.6 [55.8-253.3] 39.0 [27.6-55.7] 16.2 [-2.9-27.5] 
Demographics    
Age (years) 59.4 ±8.5 59.9 ±8.6 59.9 ±8.5 

















Prior cardiovascular disease 43 (17.4) 41 (16.6) 50 (20.2) 



















Low (women ≤ 7 glasses/week; men ≤ 14 glasses/week) 













Metabolic variables    
BMI categories 
Normal weight (< 25 kg/m2) 
Overweight (25-30 kg/m2) 



































Women 0.87 ±0.07 0.88 ±0.07 0.90 ±0.08 
Office systolic blood pressure (mmHg) 136.4 ±18.3 136.0 ±18.6 139.6 ±20.0 
Office diastolic blood pressure (mmHg) 76.7 ±10.4 75.7 ±10.4 78.1 ±10.7 
24h average ambulatory systolic blood pressure (mmHg)*  118.6 ±11.7 119.1 ±12.4 120.8 ±12.3 
24h average ambulatory diastolic blood pressure (mmHg)* 73.9 ±7.3 74.1 ±7.4 74.6 ±7.2 
Hypertension 135 (54.7) 137 (55.5) 158 (64.0) 
Glucose metabolism status 
Normal glucose metabolism 
Impaired fasting glucose 
Impaired glucose tolerance 
















Fasting glucose (mmol/l) 
Without type 2 diabetes 











Without type 2 diabetes 










Total cholesterol (mmol/l) 5.5 ±1.2 5.2 ±1.1 5.0 ±1.1 












LDL cholesterol (mmol/l) 3.5 ±1.1 3.3 ±1.0 3.1 ±1.0 
Triglycerides (mmol/l) 1.20 [0.79-1.76] 1.19 [0.86-1.66] 1.31 [0.90-1.92] 
Total-to-HDL cholesterol ratio 4.2 ±1.2 4.2 ±1.3 4.3 ±1.2 
Kidney function    
Estimated GFR (ml/min/1.73m2) 89.1 ±14.1 87.3 ±15.4 87.8 ±15.7 
Albumin excretion rate (mg/24h) 8.2 [5.4-11.1] 7.4 [5.4-11.4] 7.9 [5.5-16.6] 
Albumin excretion ≥ 15 mg/24h 31 (12.6) 38 (15.4) 66 (26.7) 
Albumin excretion ≥ 30 mg/24h 9 (3.6) 16 (6.5) 32 (13.0) 
Medication    
Antihypertensive medication 91 (36.8) 88 (35.6) 117 (47.4) 
Renin-angiotensin system inhibitor 73 (29.6) 59 (23.9) 92 (37.2) 
Lipid-modifying medication 85 (34.4) 75 (30.4) 111 (44.9) 
Data are presented as n (%), mean ±standard deviation, median [interquartile range] or (only for the percentage recruitment during 
venous congestion) median [range]. * 24h average ambulatory blood pressure measurements were missing in n = 76 participants 
(n=23 for T1, n=28 for T2 and n=25 for T3). ** To convert to HbA1c values in mmol/mol: (10.93 * HbA1c [%]) - 23.5. 
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Supplemental Table 2A. Association between the percentage recruitment during post-occlusive peak reactive hyperemia as well as 
venous congestion and the presence of albuminuria (albumin excretion ≥ 30 mg/24h) in participants without type 2 diabetes 
 
Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24h) in the respective tertile of the percentage recruitment during post-occlusive peak 
reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex; Model 3a: model 2 + 
waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, estimated GFR, 
prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic blood pressure 
instead of office systolic blood pressure (n=477). CI: confidence interval, OR: odds ratio, T: tertile. 
  
Model Recruitment during post-occlusive 
peak reactive hyperemia (%) 
OR (95% CI) P value Recruitment during 
venous congestion (%) 








0.92 (0.24; 3.48) 











2.68 (0.68; 10.52) 












0.85 (0.22; 3.25) 











2.67 (0.68; 10.57) 












0.97 (0.25; 3.85) 











2.69 (0.66; 11.01) 












1.15 (0.27; 4.96) 











3.80 (0.74; 19.66) 







Supplemental Table 2B. Association between the percentage recruitment during post-occlusive peak reactive hyperemia as well as 
venous congestion and the presence of albuminuria (albumin excretion ≥ 30 mg/24h) in participants with type 2 diabetes 
 
Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24h) in the respective tertile of the percentage recruitment during post-occlusive peak 
reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex; Model 3a: model 2 + 
waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, estimated GFR, 
prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic blood pressure 
instead of office systolic blood pressure (n=188). CI: confidence interval, OR: odds ratio, T: tertile 
  
Model Recruitment during post-occlusive 
peak reactive hyperemia (%) 
OR (95% CI) P value Recruitment during  
venous congestion (%) 








0.76 (0.26; 2.21) 











0.99 (0.33; 3.02) 












0.67 (0.23; 1.99) 











0.94 (0.30; 2.91) 












0.82 (0.26; 2.59) 











1.19 (0.36; 3.95) 












1.16 (0.34; 3.97) 











1.04 (0.29; 3.67) 







Supplemental Table 3A. Association between the absolute number of capillaries during post-occlusive peak reactive hyperemia as 
well as venous congestion and the presence of albuminuria (albumin excretion ≥ 30 mg/24h) in participants without type 2 diabetes 
 
Odds ratios represent the odds of having albuminuria (albumin excretion ≥ 30 mg/24h) in the respective tertile of the absolute number of capillaries during post-occlusive peak reactive 
hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex; Model 3a: model 2 + waist 
circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, estimated GFR, prevalent 
cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic blood pressure instead of 
office systolic blood pressure (n=477). CI: confidence interval, OR: odds ratio, T: tertile. 
  
Model Post-occlusive peak reactive 
hyperemia (n/mm2) 








2.71 (0.71; 10.39) 











1.82 (0.52; 6.33) 












2.49 (0.65; 9.62) 











1.57 (0.45; 5.53) 












2.48 (0.63; 9.81) 











1.84 (0.51; 6.62) 












2.16 (0.52; 8.86) 











2.48 (0.60; 10.29) 







Supplemental Table 3B. Association between the absolute number of capillaries during post-occlusive peak reactive hyperemia as 
well as venous congestion and the presence of albuminuria (albumin excretion ≥ 30 mg/24h) in participants with type 2 diabetes 
 
Odds ratios represent the odds of having albuminuria (albumin excretion ≥ 30 mg/24h) in the respective tertile of the absolute number of capillaries during post-occlusive peak reactive 
hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex; Model 3a: model 2 + waist 
circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, estimated GFR, prevalent 
cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic blood pressure instead of 
office systolic blood pressure (n=188). CI: confidence interval, OR: odds ratio, T: tertile 
  
Model Post-occlusive peak reactive 
hyperemia (n/mm2) 








2.47 (0.88; 6.92) 











0.81 (0.31; 2.14) 












2.19 (0.77; 6.23) 











0.68 (0.25; 1.84) 












2.84 (0.91; 8.88) 











0.76 (0.26; 2.25) 












2.16 (0.60; 7.71) 











0.78 (0.23; 2.71) 







Supplemental Table 4A. Descriptive information of the tertiles of the respective capillaroscopy measures 
 Percentage recruitment during 
post-occlusive peak reactive 
hyperemia (%) 
Percentage recruitment during 
venous congestion (%) 
Absolute number of capillaries 
during post-occlusive peak 
reactive hyperemia (n/mm2) 
Absolute number of capillaries 
during venous congestion 
(n/mm2) 
Tertile Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h  
(n (%)) 
1 55.0-186.7 12 (4.9%) 55.8-253.3 9 (3.6%) 111.5-161.0 9 (3.7%) 111.5-170.0 14 (5.6%) 
2 27.0-54.9 13 (5.3%) 27.6-55.7 16 (6.5%) 97.0-111.0 22 (8.8%) 97.0-111.0 16 (6.4%) 
3 0.0-26.9 32 (13.0%) -2.9-27.5 32 (13.0%) 43.0-96.5 26 (10.4%) 48.0-96.5 27 (11.2%) 
 
Supplemental Table 4B. Descriptive information of the quintiles of the respective capillaroscopy measures 
 Percentage recruitment during 
post-occlusive peak reactive 
hyperemia (%) 
Percentage recruitment during 
venous congestion (%) 
Absolute number of capillaries 
during post-occlusive peak 
reactive hyperemia (n/mm2) 
Absolute number of capillaries 
during venous congestion 
(n/mm2) 
Quintile Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
1 68.8-186.7 5 (3.4%) 69.8-253.3 6 (4.1%) 118.5-161.0 7 (4.8%) 119.5-170.0 5 (3.4%) 
2 49.1-68.7 11 (7.4%) 47.7-69.6 6 (4.1%) 108.0-118.0 8 (5.2%) 108.5-119.0 12 (7.9%) 
3 31.7-49.0 6 (4.0%) 32.3-47.6 12 (8.1%) 99.5-107.5 12 (8.5%) 100.0-108.0 8 (5.5%) 
4 18.9-31.4 11 (7.4%) 18.7-32.2 10 (6.8%) 89.5-99.0 16 (10.5%) 91.0-99.5 19 (12.7%) 
5 0.0-18.7 24 (16.2%) -2.9-18.6 23 (15.5%) 43.0-89.0 14 (9.5%) 48.0-90.5 13 (8.8%) 
 
Supplemental Table 4C. Descriptive information of the deciles of the respective capillaroscopy measures 
 Percentage recruitment during 
post-occlusive peak reactive 
hyperemia (%) 
Percentage recruitment during 
venous congestion (%) 
Absolute number of capillaries 
during post-occlusive peak 
reactive hyperemia (n/mm2) 
Absolute number of capillaries 
during venous congestion 
(n/mm2) 
Decile Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
Range ≥ 30 mg/24h 
(n (%)) 
1 88.6-186.7 2 (2.7%) 89.0-253.3 2 (2.7%) 125.5-161.0 3 (3.9%) 126.5-170.0 2 (2.7%) 
2 68.8-88.3 3 (4.1%) 69.8-88.3 4 (5.4%) 118.5-125.0 4 (5.6%) 119.5-126.0 3 (4.2%) 
3 59.1-68.7 4 (5.4%) 59.2-69.6 2 (2.7%) 113.0-118.0 2 (2.5%) 113.0-119.0 6 (7.4%) 
4 49.1-58.8 7 (9.5%) 47.7-59.0 4 (5.4%) 108.0-112.5 6 (8.1%) 108.5-112.5 6 (8.5%) 
5 39.5-49.0 2 (2.7%) 39.1-47.6 3 (4.1%) 104.0-107.5 5 (6.8%) 103.5-108.0 1 (1.4%) 
6 31.7-39.0 4 (5.3%) 32.3-39.0 9 (12.0%) 99.5-103.5 7 (10.3%) 100.0-103.0 7 (9.3%) 
7 24.8-31.4 5 (6.8%) 25.4-32.3 5 (6.8%) 95.5-99.0 10 (12.8%) 96.0-99.5 5 (6.8%) 
8 18.9-24.6 6 (8.1%) 18.7-25.3 5 (6.8%) 89.5-95.0 6 (8.1%) 91.0-95.5 14 (18.4%) 
9 12.8-18.7 11 (14.9%) 12.7-18.6 14 (18.9%) 82.0-89.0 7 (9.5%) 82.0-90.5 6 (8.2%) 




Supplemental Table 5A. Association between the percentage recruitment during post-occlusive peak reactive hyperemia as well as 






















Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24) in the respective quintile of the percentage recruitment during post-occlusive peak 
reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference quintile. Model 1: unadjusted model; Model 2: age, sex, type 2 diabetes; Model 
3a: model 2 + waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, 
estimated GFR, prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic 
blood pressure instead of office systolic blood pressure (n=665). CI: confidence interval, OR: odds ratio, Q: quintile. 
Model Recruitment during post-occlusive 
peak reactive hyperemia (%) 
OR (95% CI) P value Recruitment during 
venous congestion (%) 










2.30 (0.78; 6.78) 
1.20 (0.36; 4.02) 
2.30 (0.78; 6.78) 















1.00 (0.32; 3.18) 
2.07 (0.76; 5.68) 
1.72 (0.61; 4.85) 
















2.03 (0.67; 6.14) 
0.95 (0.28; 3.24) 
1.62 (0.53; 4.94) 















0.92 (0.29; 3.00) 
1.59 (0.56; 4.46) 
1.33 (0.46; 3.85) 
















2.23 (0.70; 7.09) 
1.20 (0.34; 4.25) 
1.74 (0.55; 5.52) 















0.98 (0.29; 3.34) 
1.78 (0.60; 5.26) 
1.40 (0.46; 4.24) 
















1.59 (0.47; 5.44) 
1.23 (0.34; 4.45) 
1.49 (0.45; 4.90) 















0.89 (0.24; 3.32) 
1.64 (0.53; 5.03) 
1.18 (0.37; 3.80) 









Supplemental Table 5B. Association between the absolute number of capillaries during post-occlusive peak reactive hyperemia as 






















Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24h) in the respective quintile of the absolute number of capillaries during post-
occlusive peak reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference quintile. Model 1: unadjusted model; Model 2: age, sex, type 2 
diabetes; Model 3a: model 2 + waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive 
medication, estimated GFR, prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average 
ambulatory systolic blood pressure instead of office systolic blood pressure (n=665). CI: confidence interval, OR: odds ratio, Q: quintile. 
Model Post-occlusive peak reactive 
hyperemia (n/mm2) 










1.10 (0.39; 3.10) 
1.86 (0.71; 4.87) 
2.35 (0.94; 5.90) 















2.42 (0.83; 7.04) 
1.64 (0.52; 5.12) 
4.09 (1.49; 11.27) 
















0.96 (0.33; 2.79) 
1.56 (0.58; 4.20) 
2.20 (0.85; 5.68) 















1.95 (0.65; 5.85) 
1.18 (0.37; 3.80) 
3.40 (1.20; 9.69) 
















0.86 (0.28; 2.65) 
1.67 (0.59; 4.74) 
2.12 (0.78; 5.72) 















1.76 (0.56; 5.54) 
1.37 (0.41; 4.67) 
3.23 (1.07; 9.79) 
















0.85 (0.26; 2.73) 
1.23 (0.40; 3.80) 
1.92 (0.68; 5.42) 















1.45 (0.43; 4.91) 
1.33 (0.37; 4.78) 
3.33 (1.04; 10.59) 









Supplemental Table 6A. Association between the percentage recruitment during post-occlusive peak reactive hyperemia as well as 





















Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24) in the respective decile of the percentage recruitment during post-occlusive peak 
reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference decile. Model 1: unadjusted model; Model 2: age, sex, type 2 diabetes. CI: 
confidence interval, OR: odds ratio, D: decile. 
  
Model Recruitment during post-occlusive 
peak reactive hyperemia (%) 
OR (95% CI) P value Recruitment during 
venous congestion (%) 















1.52 (0.25; 9.38) 
2.06 (0.37; 11.59) 
3.76 (0.76; 18.75) 
1.00 (0.14; 7.29) 
2.02 (0.36; 11.43) 
2.61 (0.49; 13.90) 
3.18 (0.62; 16.28) 
6.29 (1.34; 29.44) 

























2.06 (0.37; 11.59) 
1.00 (0.14; 7.29) 
2.06 (0.37; 11.59) 
1.52 (0.25; 9.38) 
4.91 (1.02; 23.55) 
2.61 (0.49; 13.90) 
2.61 (0.49; 13.90) 
8.40 (1.84; 38.43) 


























1.46 (0.23; 9.24) 
1.98 (0.34; 11.49) 
2.96 (0.57; 15.26) 
0.75 (0.10; 5.59) 
1.16 (0.28; 9.35) 
1.64 (0.30; 9.01) 
2.45 (0.46; 13.03) 
3.92 (0.81; 19.07) 

























1.91 (0.33; 11.05) 
0.91 (0.12; 6.77) 
1.80 (0.31; 10.40) 
1.16 (0.18; 7.40) 
3.50 (0.71; 17.33) 
1.94 (0.35; 10.64) 
1.96 (0.36; 10.81) 
4.70 (0.98; 22.50) 














Supplemental Table 6B. Association between the absolute number of capillaries during post-occlusive peak reactive hyperemia as 





















Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 30 mg/24h) in the respective decile of the absolute number of capillaries during post-occlusive 
peak reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference decile. Model 1: unadjusted model; Model 2: age, sex, type 2 diabetes. 
CI: confidence interval, OR: odds ratio, D: decile. 
 
  
Model Post-occlusive peak reactive 
hyperemia (n/mm2) 















1.45 (0.31; 6.73) 
0.62 (0.10; 3.84) 
2.15 (0.52; 8.93) 
1.79 (0.41; 7.77) 
2.79 (0.69; 11.26) 
3.58 (0.95; 13.56) 
2.15 (0.52; 8.93) 
2.54 (0.63; 10.23) 

























1.57 (0.25; 9.66) 
2.88 (0.56; 14.74) 
3.32 (0.65; 17.05) 
0.51 (0.05; 5.80) 
3.71 (0.74; 18.47) 
2.61 (0.49; 13.90) 
8.13 (1.78; 37.17) 
3.22 (0.63; 16.53) 


























1.83 (0.38; 8.92) 
0.59 (0.09; 3.78) 
2.16 (0.50; 9.38) 
1.49 (0.33; 6.75) 
2.96 (0.70; 12.54) 
3.92 (0.99; 15.61) 
2.12 (0.49; 9.23) 
1.98 (0.49; 8.78) 

























2.04 (0.32; 13.16) 
2.60 (0.49; 13.81) 
3.08 (0.58; 16.51) 
0.45 (0.04; 5.20) 
2.88 (0.56; 14.94) 
2.57 (0.46; 14.24) 
7.42 (1.56; 35.41) 
2.67 (0.50; 14.79) 














Supplemental Table 7A. Association between the percentage recruitment during post-occlusive peak reactive hyperemia as well as 
venous congestion and the presence of albuminuria (albumin excretion ≥ 15 mg/24h)  
 
Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 15 mg/24) in the respective tertile of the percentage recruitment during post-occlusive peak 
reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex, type 2 diabetes; Model 
3a: model 2 + waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, 
estimated GFR, prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic 
blood pressure instead of office systolic blood pressure (n=665). CI: confidence interval, OR: odds ratio, T: tertile. 
  
Model Recruitment during post-occlusive 
peak reactive hyperemia (%) 
OR (95% CI) P value Recruitment during 
venous congestion (%) 








1.10 (0.67; 1.83) 











1.27 (0.76; 2.11) 












0.86 (0.50; 1.46) 











1.09 (0.64; 1.86) 












0.92 (0.53; 1.60) 











1.10 (0.63; 1.91) 












1.03 (0.57; 1.84) 











1.16 (0.65; 2.08) 







Supplemental Table 7B. Association between the absolute number of capillaries during post-occlusive peak reactive hyperemia as 
well as venous congestion and the presence of albuminuria (albumin excretion ≥ 15 mg/24h) 
 
Odds ratios represent the odds of having albuminuria (defined as an albumin excretion ≥ 15 mg/24h) in the respective tertile of the absolute number of capillaries during post-occlusive 
peak reactive hyperemia or venous congestion compared with the odds of having albuminuria in the reference tertile. Model 1: unadjusted model; Model 2: age, sex, type 2 diabetes; 
Model 3a: model 2 + waist circumference, total-to-HDL cholesterol ratio, triglycerides, use of lipid-modifying drugs, office systolic blood pressure, use of antihypertensive medication, 
estimated GFR, prevalent cardiovascular disease, smoking behavior, alcohol consumption, educational level; Model 3b: as model 3a but adjusted for 24h average ambulatory systolic 
blood pressure instead of office systolic blood pressure (n=665). CI: confidence interval, OR: odds ratio, T: tertile. 
 
Model Post-occlusive peak reactive 
hyperemia (n/mm2) 








1.71 (1.05; 2.79) 











1.31 (0.81; 2.14) 












1.57 (0.94; 2.63) 











1.15 (0.69; 1.93) 












1.75 (1.02; 2.99) 











1.28 (0.75; 2.18) 












1.45 (0.82; 2.57) 











1.17 (0.66; 2.09) 
1.92 (1.11; 3.33) 
 
 
0.591 
0.019 
